Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P12259
UPID:
FA5_HUMAN
Alternative names:
Activated protein C cofactor; Proaccelerin, labile factor
Alternative UPACC:
P12259; A8K6E8; Q14285; Q2EHR5; Q5R346; Q5R347; Q6UPU6; Q8WWQ6
Background:
Coagulation factor V, also known as Proaccelerin or Activated protein C cofactor, plays a pivotal role in hemostasis. It acts as an essential cofactor for the prothrombinase activity of factor Xa, leading to the conversion of prothrombin to thrombin. This process is central to the blood coagulation cascade, ensuring proper clot formation.
Therapeutic significance:
Factor V deficiency, Thrombophilia due to activated protein C resistance, Budd-Chiari syndrome, Ischemic stroke, and recurrent Pregnancy loss are all linked to genetic variants affecting Factor V. Understanding its role could lead to targeted therapies for these conditions, highlighting its importance in vascular health and disease.